Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas

Stem Cells Translational Medicine

Volumn 2, Issue 1, 2013, Pages 53-60

  Wirths, Stefan ^a   Malenke, Elke ^a   Kluba, Torsten ^a   Rieger, Simone ^a   Müller, Martin R ^a   Schleicher, Sabine ^b   von Weyhern, Claus Hann ^a   Nagl, Florian ^a   Fend, Falko ^a   Vogel, Wichard ^a   Mayer, Frank ^a   Kanz, Lothar ^a   Bühring, Hans Jörg ^a   Kopp, Hans Georg ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cancer stem cell; Mesenchymal stem cell; Sarcoma stem cell; Stem cell marker

Indexed keywords

ALKALINE PHOSPHATASE; CD133 ANTIGEN; CD177 ANTIGEN; CD271 ANTIGEN; CD344 ANTIGEN; CELL SURFACE MARKER; DOXORUBICIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MEMBRANE ANTIGEN; TUMOR MARKER;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOARCHITECTURE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SKELETAL MUSCLE; SMOOTH MUSCLE; SOFT TISSUE SARCOMA; CANCER STEM CELL; CELL SHAPE; DRUG EFFECT; DRUG RESISTANCE; MESENCHYMAL STROMA CELL; METABOLISM; MULTICELLULAR SPHEROID; SARCOMA; TUMOR CELL CULTURE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, SURFACE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASTIC STEM CELLS; SARCOMA; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84873471051     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0055     Document Type: Article

References (34)

1. Kopp HG, Patel S, Brucher B et al. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol 2008;9:207-217.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
3. Fletcher CDM, Unni KK, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press, 2002.
4. Katenkamp D, Kosmehl H. Heterogeneity in malignant soft tissue tumors. Curr Top Pathol 1995;89:123-151.
5. Katenkamp D. Cellular heterogeneity: Explanation for changing of tumor phenotype and biologic behavior in soft tissue sarcomas. Pathol Res Pract 1988;183:698-705.
6. McArthur GA, Demetri GD, Van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-873.
7. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-1134.
8. Nielsen TO, West RB. Translating gene expression into clinical care: Sarcomas as a paradigm. J Clin Oncol 2010;28:1796-1805.
9. Jin L, Hope KJ, Zhai Q et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12:1167-1174.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
11. Kim CF, Jackson EL, Woolfenden AE et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121: 823-835.
12. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
13. Charytonowicz E, Cordon-Cardo C, Matushansky I et al. Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell? Cancer Lett 2009;279:126-136.
14. Li N, Yang R, Zhang W et al. Genetically transforming human mesenchymal stem cells to sarcomas: Changes in cellular phenotype and multilineage differentiation potential. Cancer 2009;115:4795-4806.
15. Serakinci N, Guldberg P, Burns JS et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004;23:5095-5098.
16. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. STEM CELLS 2007;25:371-379.
17. Rodriguez R, Rubio R, Gutierrez-Aranda I et al. Fus-Chop fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not human adipose-derived mesenchymal stem/ stromal cells. STEM CELLS 2010;29:179-192.
18. Rubio R, Garcia-Castro J, Gutierrez-Aranda I et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010;70:4185-4194.
19. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
20. Bühring HJ, Battula VL, Treml S et al. Novel markers for the prospective isolation of human MSC. Ann NY Acad Sci 2007;1106: 262-271.
21. Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 2003;9: 1941-1956.
22. Battula VL, Treml S, Bareiss PM et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009;94:173-184.
23. Bühring HJ, Treml S, Cerabona F et al. Phenotypic characterization of distinct human bone marrow-derived MSC subsets. Ann NY Acad Sci 2009;1176:124-134.
24. Haniffa MA, Collin MP, Buckley CD et al. Mesenchymal stem cells: The fibroblasts' new clothes? Haematologica 2009;94:258-263.
25. Quirici N, Soligo D, Bossolasco P et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002;30:783-791.
26. Fujii H, Honoki K, Tsujiuchi T et al. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 2009;34:1381-1386.
27. Brune JC, Tormin A, Johansson MC et al. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int J Cancer 2011;129:319-330.
28. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells: Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
29. Vogel W, Grunebach F, Messam CA et al. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica 2003;88:126-133.
30. Sobiesiak M, Sivasubramaniyan K, Hermann C et al. The mesenchymal stem cell antigen MSCA-1 is identical to tissue non-specific alkaline phosphatase. Stem Cells Dev 2010;19: 669-677.
31. Yamamoto N, Akamatsu H, Hasegawa S et al. Isolation of multipotent stem cells from mouse adipose tissue. J Dermatol Sci 2007;48: 43-52.
32. Boiko AD, Razorenova OV, van de RM et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-137.
33. Dechant G, Barde YA. The neurotrophin receptor p75(NTR): Novel functions and implications for diseases of the nervous system. Nat Neurosci 2002;5:1131-1136.
34. Smallwood PM, Williams J, Xu Q et al. Mutational analysis of Norrin-Frizzled4 recognition. J Biol Chem 2007;282:4057-4068.